Cas:176433-55-9 6-chloro-5-hydroxypyridine-3-carbaldehyde manufacturer & supplier

We serve Chemical Name:6-chloro-5-hydroxypyridine-3-carbaldehyde CAS:176433-55-9 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

6-chloro-5-hydroxypyridine-3-carbaldehyde

Chemical Name:6-chloro-5-hydroxypyridine-3-carbaldehyde
CAS.NO:176433-55-9
Synonyms:6-chloro-5-hydroxy-3-pyridinecarboxaldehyde;6-chloro-5-hydroxynicotinaldehyde;6-chloro-5-hydroxy-pyridine-3-carbaldehyde
Molecular Formula:C6H4ClNO2
Molecular Weight:157.55400
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:50.19000
Exact Mass:156.99300
LogP:1.25310

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 6-chloro-5-hydroxy-3-pyridinecarboxaldehyde chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,6-chloro-5-hydroxy-pyridine-3-carbaldehyde physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,6-chloro-5-hydroxy-pyridine-3-carbaldehyde Use and application,6-chloro-5-hydroxy-3-pyridinecarboxaldehyde technical grade,usp/ep/jp grade.


Related News: The Transport Security Administration (TSA) will issue a new security directive to airlines from Sunday, according to a person briefed on the restrictions. 6-chloro-5-hydroxypyridine-3-carbaldehyde manufacturer Alira’s work spans the gamut from transaction advisory to regulatory services to advanced analytics, management consulting, product development and clinical investigator training, to name a few. With the CROS NT deal, Alira secures not only a biometrics presence but also a portfolio of electronic data capture systems. 6-chloro-5-hydroxypyridine-3-carbaldehyde supplier Currently allowed as a second-line treatment, Sarclisa is expected to have top-line data from the phase 3 IMROZ trial later this year. The trial is adding Sarclisa to a VRd cocktail of Velcade, Revlimid and dexamethasone, which has established itself as the standard-of-care first-line therapy for patients with myeloma. 6-chloro-5-hydroxypyridine-3-carbaldehyde vendor The Transport Security Administration (TSA) will issue a new security directive to airlines from Sunday, according to a person briefed on the restrictions. 6-chloro-5-hydroxypyridine-3-carbaldehyde factory During analysis of the clinical trial data, the researchers realized that about a third of the participants had low levels of abnormal tau protein, which makes them not very suitable for evaluating the effects of a treatment halting the progression of tau pathology.